ImmunityBio Inc. IBRX on Monday said it entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory ...

Stock Moves Higher Following Patent Announcement Shares of ImmunityBio (NASDAQ:IBRX) gained 4.5% in premarket trading on ...

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Five issued U.S. patents cover the combination of ImmunityBio’s IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin ...

The Scottish medicines consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults with ...

Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now ...

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the cancer more resistant to treatment, according to new research from ...

An innovative treatment for bladder cancer successfully prevented the recurrence of tumors and improved survival rates following surgery.

But when Jimi began experiencing bladder cancer symptoms, including blood in his urine, he felt a different kind of rush. It was the kind that puts you into shock. “Cancer was definitely something ...

Urinary tract infections (UTIs) commonly occur in people who undergo chemotherapy. The treatment can weaken the immune system and damage barriers, such as the skin and mucous membranes, that help ...